Trial Profile
The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Peginterferon lambda-1a (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Nanogen Biopharmaceutical Co
- 13 Dec 2016 Status changed from recruiting to completed.
- 15 Mar 2014 New trial record